Tobinick_edited.qxp 6/8/08 9:51 am Page 36
Alzheimer’s Disease
1. Hock C, Konietzko U, Streffer JR, et al., Antibodies against beta- 14. Tobinick E, TNF inhibitors for the treatment of neurological candidates and targets, Curr Alzheimer Res, 2007; 4(4):375–8.
amyloid slow cognitive decline in Alzheimer’s disease, Neuron, disorders, US patent 6,177,077, filed 1999. 28. Van Eldik LJ, Thompson WL, Ranaivo HR, Proinflammatory cytokine
2003;38(4):547–54. 15. Tobinick E, Tumor necrosis factor antagonists for the treatment of upregulation as a therapeutic target for neurodegenerative
2. Thatte U, AN-1792 (Elan), Curr Opin Investig Drugs, neurological disorders, US patent 6,015,557, filed 1999. diseases: function-based and target-based discovery approaches,
2001;2(5):663–7. 16. Amgen, Enbrel(R) package insert, 2005, Thousand Oaks, CA. International Review of Neurobiology, 2007;82:278–97.
3. Orgogozo JM, Gilman S, Dartigues JF, et al., Subacute 17. Chiarini A, Dal Pra I, Whitfield JF, and Armato U, The killing of 29. Wang Q, Wu J, Rowan MJ, and Anwyl R, Beta-amyloid inhibition of
meningoencephalitis in a subset of patients with AD after Abeta42 neurons by beta-amyloid peptides, prions, and pro-inflammatory long-term potentiation is mediated via tumor necrosis factor, Eur J
immunization, Neurology, 2003;61(1):46–54. cytokines, Ital J Anat Embryol, 2006;111(4):221–46. Neurosci, 2005; 22(11):2827–32.
4. Black RS, Sperling R, Kirby L, et al., A single ascending dose study 18. Laws SM, Perneczky R, Wagenpfeil S, et al., TNF polymorphisms in 30. Banks, WA, Plotkin SR, and Kastin AJ, Permeability of the blood-
of bapineuzumab, a humanized monoclonal antibody to A-beta, in Alzheimer disease and functional implications on CSF beta- brain barrier to soluble cytokine receptors,
AD, 9th International Geneva/Springfield Symposium on Advances amyloid levels, Hum Mutat, 2005;26(1):29–35. Neuroimmunomodulation, 1995; 2(3):161–5.
in Alzheimer Therapy, 2006, Geneva, Switzerland. 19. Lio D, Annoni G, Licastro F, Tumor necrosis factor-alpha -308A/G 31. Bohac D, Burke W, Cotter R, et al., A 24-week randomized,
5. Pfeifer M, Boncristiano S, Bondolfi L, et al., Cerebral hemorrhage polymorphism is associated with age at onset of Alzheimer’s double-blind, placebo-controlled study of the efficacy and
after passive anti-Abeta immunotherapy, Science, disease, Mech Ageing Dev, 2006;127(6):567–71. tolerability of TNFR: Fc (etanercept) in the treatment of dementia
2002;298(5597):1379. 20. Medeiros R, Prediger RD, Passos GF, et al., Connecting TNF-{alpha} of the Alzheimer type, Neurobiol Aging, 2002;23(1 Suppl. 1):
6. Solomon B, Intravenous immunoglobulin and Alzheimer’s disease signaling pathways to iNOS expression in a mouse model of S1–606, abstract 315.
immunotherapy, Curr Opin Mol Ther, 2007;9(1):79–85. Alzheimer’s disease: relevance for the behavioral and synaptic 32. Tobinick EL and Britschgi-Davoodifar S, Perispinal TNF-alpha
7. Dodel R, Hampel H, Depboylu C, et al., Human antibodies against deficits Induced by amyloid {beta} protein, J Neurosci, inhibition for discogenic pain, Swiss Med Wkly, 2003;133(11–12):
amyloid beta peptide: a potential treatment for Alzheimer’s 2007;27(20):5394–404. 170–7.
disease, Ann Neurol, 2002;52(2):253–6. 21. Perry RT, Collins JS, Wiener H, et al., The role of TNF and its 33. Tobinick E and Davoodifar S, Efficacy of etanercept delivered by
8. Dodel RC, Du Y, Depboylu C, et al., Intravenous immunoglobulins receptors in Alzheimer’s disease, Neurobiol Aging, perispinal administration for chronic back and/or neck disc-related
containing antibodies against beta-amyloid for the treatment of 2001;22(6):873–83. pain: a study of clinical observations in 143 patients, Curr Med Res
Alzheimer’s disease, J Neurol Neurosurg Psychiatry, 22. Pickering M, Cumiskey D, and O’Connor JJ, Actions of TNF-alpha Opin, 2004;20(7):1075–85.
2004;75(10):1472–4. on glutamatergic synaptic transmission in the central nervous 34. Tobinick E, Gross H, Weinberger A, and Cohen H, TNF-alpha
9. Relkin R, Tsakanikas D, Adamiak B, et al., A double blind, placebo- system, Exp Physiol, 2005;90(5):663–70. modulation for treatment of Alzheimer’s disease: a 6-month pilot
controlled, phase II clinical trial of IVIG for treatment of 23. Ramos, EM, Lin MT, Larson EB, et al., Tumor necrosis factor alpha study, Medscape General Medicine, 2006;8(2):25f.
Alzheimer’s disease, American Academy of Neurology 60th Annual and interleukin 10 promoter region polymorphisms and risk of 35. Tobinick E, Perispinal etanercept for treatment of Alzheimer’s
Meeting, 2008, Chicago, Illinois. late-onset Alzheimer disease, Arch Neurol, 2006;63(8):1165–9. disease, Curr Alzheimer Res, 2007;4(5):550–52.
10. Katz U, Achiron A, Sherer Y, and Shoenfeld Y, Safety of intravenous 24. Ranaivo HR, Craft JM, Hu W, et al., Glia as a therapeutic target: 36. Tobinick E and Vega C, The cerebrospinal venous system: anatomy,
immunoglobulin (IVIG) therapy, Autoimmunity Reviews, selective suppression of human amyloid-beta-induced physiology, and clinical implications, MedGenMed, 2006;8(1):53.
2007;6(4):257–9. upregulation of brain proinflammatory cytokine production 37. Tobinick EL and Gross H, Rapid cognitive improvement in
11. Clark IA, How TNF was recognized as a key mechanism of disease, attenuates neurodegeneration, J Neurosci, 2006; 26(2):662–70. Alzheimer’s disease following perispinal etanercept administration,
Cytokine Growth Factor Rev, 2007;18(3-4):335–43. 25. Rowan MJ, Klyubin I, Wang Q, et al., Synaptic memory J Neuroinflammation, 2008;5:2.
12. Tarkowski E, Blennow K, Wallin A, and Tarkowski A, Intracerebral mechanisms: Alzheimer’s disease amyloid beta-peptide-induced 38. Griffin WS, Perispinal etanercept: potential as an Alzheimer
production of tumor necrosis factor-alpha, a local neuroprotective dysfunction, Biochem Soc Trans, 2007;35(Pt 5):1219–23. therapeutic, J Neuroinflammation, 2008;5(1):3.
agent, in Alzheimer disease and vascular dementia, J Clin 26. Tan ZS, Beiser AS, Vasan RS, Inflammatory markers and the risk of 39. Bains JS and Oliet SH, Glia: they make your memories stick!,
Immunol, 1999;19(4):223–30. Alzheimer disease: the Framingham Study, Neurology, Trends Neurosci, 2007;30(8):417–24.
13. Tarkowski E, Andreasen N, Tarkowski A, and Blennow K, 2007;68(22):1902–8. 40. Multiple pending and issued US patents issued to Edward
Intrathecal inflammation precedes development of Alzheimer’s 27. Tweedie D, Sambamurti K, and Greig NH, TNF-alpha inhibition as Tobinick, assigned to TACT IP, LLC, including, but not limited to,
disease, J Neurol Neurosurg Psychiatry, 2003;74(9):1200–5. a treatment strategy for neurodegenerative disorders: new drug US patents 6,982,089 and 7,214,658.
Impact of Increased Life Expectancy on Alzheimer’s Disease Death Rate
More women than men have Alzheimer’s/other dementias, primarily
Percentage of Medicare Beneficiaries Aged 65+ Years with
because on average women live longer than men and their longer
Alzheimer’s Disease/Other Dementias Who Had Specified
life expectancy means females are more susceptible to developing
Co-existing Medical Conditions
neurological conditions.
60
Impact of Co-existing Medical Conditions
Most people with Alzheimer’s/other dementias have one
50
or more other serious medical conditions. For example, 30%
of Medicare beneficiaries aged 65 years and over with Alzheimer’s/
c
ondition 40
other dementias also have coronary heart disease, while 28% have s or other dementias
congestive heart failure. 30
c
o-existing
However, deaths from diseases such as heart disease and cancer are
20
declining, which, since 2000, has led to an increase in Alzheimer’s
and the
disease death rates for the oldest age groups. For example, the
10
death rate for those aged 75–84 increased from 139.6 per 100,000
r
c
entage with Alzheimer’
Pe
0
in 2000 to 168.7 per 100,000 in 2004. People who may have died
of the above-mentioned diseases live longer, and thus have an
disease
failure
c
tive e—
c
ts
Diabetes
a
s
c
ular
disease
increased risk of dying of Alzheimer’s disease.
Strok
Hypertension
Coronary heart
Osteoarthritis
c
obstru
late effe
Congestive heart
T
hyroid disease
Source: 2008 Alzheimer’s Disease Facts and Figures, Alzheimer’s Association.
P
e
ripheral v
Chroni
pulmonary disease
36 US NEUROLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84